Tracer library / [131I]MEGMIB-5F7GGC

[131I]MEGMIB-5F7GGC

Also written as [I-131]MEGMIB-5F7GGC

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Pan-cancer / multiple tumour types Preclinical only, no clinical indication yet

What it is

Compound class: Anti-HER2 single domain antibody fragment (sdAb) radioiodinated via residualizing prosthetic agent
Target / mechanism: HER2 (human epidermal growth factor receptor 2) PMID 32448731
Clinical application: HER2-expressing tumors (e.g., ovarian carcinoma, as modeled by SKOV-3 xenografts) PMID 32448731
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	45 ± 7%	>99%	Boc2-MEGMTB	32448731 2021 Nucl Med Biol Conjugation of [131I]MEGMIB to monomeric/reduced 5F7GGC was performed adapting a previously reported method - Conjugation of [131I]MEGMIB with freshly reduced 5F7GGC was achieved in 45 ± 7% yield (n=10).

Need this precursor?We can point you to suppliers for [131I]MEGMIB-5F7GGC, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 32448731. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.